Akero Therapeutics Inc
AKRO54.650USD
0.0000.00%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
4.38BValor de mercado
PerdaP/L TTM
Mais detalhes de Akero Therapeutics Inc Empresa
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Informações de Akero Therapeutics Inc
Código da empresaAKRO
Nome da EmpresaAkero Therapeutics Inc
Data de listagemJun 20, 2019
CEOCheng (Andrew)
Número de funcionários63
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 20
Endereço601 Gateway Boulevard, Suite 350
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone16504876488
Sitehttps://akerotx.com/
Código da empresaAKRO
Data de listagemJun 20, 2019
CEOCheng (Andrew)
Executivos da empresa Akero Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.10K
-89277.00%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+8266.00%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
20.73K
-200189.00%
Mr. William White, J.D.
Mr. William White, J.D.
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
--
--
Dr. Timothy Rolph
Dr. Timothy Rolph
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Ms. Jane Pritchett Henderson
Ms. Jane Pritchett Henderson
Independent Director
Independent Director
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.10K
-89277.00%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+8266.00%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
20.73K
-200189.00%
Mr. William White, J.D.
Mr. William White, J.D.
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
--
--
Dr. Timothy Rolph
Dr. Timothy Rolph
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 31 de jan
Atualizado em: sáb, 31 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
7.63%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.08%
Wellington Management Company, LLP
5.16%
Outro
67.51%
Investidores
Investidores
Proporção
Janus Henderson Investors
7.63%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.08%
Wellington Management Company, LLP
5.16%
Outro
67.51%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
45.16%
Investment Advisor
23.71%
Hedge Fund
18.04%
Private Equity
9.73%
Research Firm
2.95%
Venture Capital
2.56%
Individual Investor
1.08%
Foundation
0.40%
Bank and Trust
0.24%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
504
92.63M
123.44%
-26.38K
2025Q3
532
92.72M
128.44%
-619.25K
2025Q2
513
93.19M
122.60%
+5.80M
2025Q1
481
87.41M
107.62%
+1.72M
2024Q4
438
74.28M
124.07%
+570.22K
2024Q3
432
73.67M
126.17%
-695.38K
2024Q2
416
72.42M
128.65%
-3.01M
2024Q1
408
73.91M
107.89%
+1.88M
2023Q4
389
59.72M
117.03%
+1.94M
2023Q3
376
57.78M
113.32%
+701.00K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
6.28M
7.63%
-458.25K
-6.80%
Sep 30, 2025
General Atlantic LLC
5.73M
6.97%
--
--
Sep 30, 2025
RTW Investments L.P.
5.48M
6.65%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.01M
6.08%
-54.14K
-1.07%
Sep 30, 2025
Wellington Management Company, LLP
4.25M
5.16%
+841.91K
+24.69%
Sep 30, 2025
Deep Track Capital LP
4.00M
4.86%
+958.38K
+31.50%
Sep 30, 2025
Avoro Capital Advisors LLC
3.96M
4.8%
+455.56K
+13.02%
Sep 30, 2025
T. Rowe Price Associates, Inc.
3.72M
4.52%
-702.58K
-15.89%
Sep 30, 2025
State Street Investment Management (US)
3.41M
4.15%
+668.74K
+24.36%
Sep 30, 2025
Bellevue Asset Management AG
2.39M
2.9%
+404.04K
+20.35%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Simplify Propel Opportunities ETF
11.66%
ProShares Merger ETF
2.71%
State Street SPDR S&P Biotech ETF
1.78%
ALPS Medical Breakthroughs ETF
1.75%
AltShares Merger Arbitrage ETF
1.63%
Direxion Daily S&P Biotech Bull 3X Shares
1.1%
ProShares Ultra Nasdaq Biotechnology
0.43%
Invesco Nasdaq Biotechnology ETF
0.42%
iShares Biotechnology ETF
0.34%
Pacer WealthShield ETF
0.28%
Ver Mais
Simplify Propel Opportunities ETF
Proporção11.66%
ProShares Merger ETF
Proporção2.71%
State Street SPDR S&P Biotech ETF
Proporção1.78%
ALPS Medical Breakthroughs ETF
Proporção1.75%
AltShares Merger Arbitrage ETF
Proporção1.63%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção1.1%
ProShares Ultra Nasdaq Biotechnology
Proporção0.43%
Invesco Nasdaq Biotechnology ETF
Proporção0.42%
iShares Biotechnology ETF
Proporção0.34%
Pacer WealthShield ETF
Proporção0.28%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
